Q2
CRSP — Q2 2026 Financial Report Analysis
CRISPR Therapeutics' Q2 2026 net loss narrowed to $91.2M from $208.5M, mostly because a $96.3M licensing charge didn't repeat; Casgevy sales rose 151% to $76M but still cost CRISPR $40.3M net, while cash reached $2.36B after a $600M convertible bond.